Cancer Biospecimen Acquisition and Biorepository

AECC癌症生物标本获取和生物库资源(CBABR)的目标是提供一个符合NCI最佳实践的集中式单位，用于癌症研究的高质量生物标本。CBABR监督从实体和血液肿瘤中采购恶性、良性、患病和未受累(正常)组织，供AECC和其他调查人员使用。CBABR是通过将多个联合的癌症相关机构生物库整合为一个面向癌症的组织采集和存储生物库而组织起来的，该生物库是未来样本收集的核心。CBABR是AECC、爱因斯坦CTSA和其他由NIH资助的爱因斯坦中心的联合努力，并得到了几项机构倡议的支持，包括爱因斯坦的临床合作伙伴蒙特菲奥里医疗中心正在使用的通用选择加入同意程序，与蒙特菲奥里外科病理学合作的组织采集专门人员，临床研究信息学支持将样本与医疗和研究记录联系起来，以及利用最先进的节能冷冻技术的专用存储空间。已经开发了一种基于网络的应用程序，允许研究人员确定CBABR中是否存在具有他们研究所需表型特征的组织。CBABR的重点是头颈癌、乳腺癌、结肠癌、肺癌、宫颈癌和卵巢癌、神经内分泌肿瘤和血液肿瘤。它目前储存了67,704个样本，包括自2011年底新的CBABR建立以来收集的5,704个样本，所有这些样本都可供调查人员使用。CBABR过程包括患者在最初的癌症评估时的知情同意，计划的普遍“选择加入” 同意程序，注明在生物显微镜上的患者医疗和健康信息， 集中管理标本采集、处理和存储，以及多级安全和 通过父CTSA生物存储库保护资源，包括全天候监控和报警 冗余备份。已经成立了CBABR科学审查委员会(SRB)，以评估科学和 向AECC议定书审查和报告报告的使用生物样品的申请的技术优点 监督委员会(PRMC)批准并在必要时确定组织使用建议的优先顺序。 还建立了要求外部调查人员进行合作的机制。一个 机构倡议将跟踪知情同意过程，并对以下项目的贡献者进行后续询问 CBSR用于评估患者的知识和满意度。

The goal of the AECC Cancer Biospecimen Acquisition and Biorepository Resource (CBABR) is to provide a centralized unit that meets the best practices of the NCI for high quality biospecimens for cancer research. The CBABR oversees the procurement of malignant, benign, diseased and uninvolved (normal) tissues from both solid and hematological tumors for use by AECC and other investigators. The CBABR has been organized through the consolidation of multiple federated cancer associated Institutional biobanks into a cohesive cancer oriented tissue acquisition and storage biobank that is the nucleus for prospective sample collection. The CBABR is a joint effort of AECC, the Einstein CTSA and other NIH funded centers at Einstein and is supported by several Institutional initiatives including a universal opt-in consent process in use by Einstein's clinical partner, Montefiore Medical Center, dedicated staffing for tissue acquisition in cooperation with Montefiore Surgical Pathology, Clinical Research Informatics support linking samples to medical and research records, and dedicated secure storage space utilizing the most advanced energy efficient freezer technology. A web-based application has been developed that allows investigators to determine if tissue exists in the CBABR with necessary phenotypic characteristics for their studies. The CBABR focus has been on head and neck cancer, breast, colon, lung, cervical and ovarian, neuroendocrine tumors, and hematological tumors. It currently houses 67,704 samples, including 5,704 samples collected since the institution of the new CBABR in late 2011, all of which are available for use by investigators. The CBABR process encompasses patient informed consent at initial cancer evaluation, planned universal "opt-in" consent procedures, patient medical and health information that is annotated to the biospecimens, centralized management of specimen collection, processing and storage, and multiple levels of security and protection of the resource through the parent CTSA biorepository including 24/7 monitoring and alarmed redundant backups. A CBABR Scientific Review Board (SRB) has been constituted to evaluate scientific and technical merit of applications for use of biospecimens that reports to the AECC Protocol Review and Monitoring Committee (PRMC) to approve and, when necessary, prioritize proposed tissue usage. Mechanisms for requested collaborations from outside investigators have been established as well. An institutional initiative will track the informed consent process and perform follow up queries on contributors to the CBSR to assess patient knowledge and satisfaction.